Intarcia raises $210 million offering hope for once-yearly diabetes treatment

November 27, 2012 | Analyst Insight

California-based Intarcia Therapeutics raised a combined $210 million to initiate a global Phase III program for a once-yearly, injection-free treatment for Type 2 diabetes. Its investors include New Enterprise Associates, Venrock, New Leaf Venture...

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978